Microlax for children, 0 to 3 years old 4 pcs.

MICROLAX® is a combined preparation with laxative effect. The effect occurs after 5-15 minutes. The preparation consists of sodium citrate (peptide, which displaces bound water contained in stools), sodium lauryl sulfoacetate (liquefies intestinal contents) and sorbitol (increases the laxative effect by stimulating water flow into the intestine).

Increase in water due to peptization and liquefaction promotes softening of stools and facilitates bowel emptying.

Indications

Constipation, incl. with encopresis, preparation for endoscopic (rectoscopy) and x-ray examination of the gastrointestinal tract.

Pharmacological effect

MICROLAX® is a combined drug that has a laxative effect. The effect occurs within 5-15 minutes. The drug contains sodium citrate (a peptizer that displaces bound water contained in stool), sodium lauryl sulfoacetate (thin the intestinal contents) and sorbitol (enhances the laxative effect by stimulating the flow of water into the intestines).

Increasing the amount of water due to peptization and liquefaction helps soften stool and facilitate bowel movements.

Special instructions

If symptoms persist, avoid long-term use and consult a doctor.

If the medicine has become unusable or has expired, do not pour it into wastewater or throw it outside! Place the medication in a bag and place it in the trash. These measures will help protect the environment!

Active ingredient

Sodium lauryl sulfoacetate, Sodium citrate, Sorbitol

Composition

One ml of solution contains:

Active substances:

sodium citrate – 90 mg,

sodium lauryl sulfoacetate 70% – 12.9 mg (corresponds to 9 mg sodium lauryl sulfoacetate),

sorbitol solution 70% – 893 mg (corresponds to 625 mg of sorbitol);

Excipients:

sorbic acid – 1 mg,

glycerol – 125 mg,

purified water to 1 ml.

Pregnancy

There have been no adequate and strictly controlled studies in pregnant women. Since this drug is likely to be absorbed into the systemic circulation to a small extent, adverse effects to the fetus or nursing infant are not expected when used as recommended during pregnancy or lactation.

Contraindications

Increased individual sensitivity to the components of the drug.

Side Effects

According to spontaneous reports of adverse events

Adverse reactions arising from the use of the drug, which were identified during post-registration use, were classified as follows: very common (≥10%), common (≥1%, but <10%), not common (≥0.1%, but <1%), rare (≥0.01%, but <0.1%), very rare (<0.01%) and adverse reactions with unknown incidence (incidence cannot be estimated from available data).Gastrointestinal disorders. Very rare: pain in the abdominal area (including abdominal discomfort, pain in the abdominal area, as well as in the upper abdomen); discomfort in the anorectal area, loose stools.Immune system disorders. Very rare: hypersensitivity reactions (eg, urticaria).

Interaction

There is a risk of developing colon necrosis with simultaneous oral/rectal use of sodium polystyrene sulfonate and sorbitol, which is part of the drug.

Overdose

Currently, cases of overdose have not been described.

Storage conditions

At a temperature not exceeding 25°C, out of the reach of children.

Shelf life

5 years

Manufacturer

Delpharm Orleans, France